Cargando…

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells

BACKGROUND AND OBJECTIVES: Secondary CNS involvement in systemic B-cell lymphoma (SCNSL) is difficult to treat and displays dismal clinical outcomes. Chimeric antigen receptor (CAR) T cells emerged as a powerful treatment for systemic lymphoma. We aimed to evaluate whether CAR T cells also represent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karschnia, Philipp, Rejeski, Kai, Winkelmann, Michael, Schöberl, Florian, Bücklein, Veit L., Blumenberg, Viktoria, Schmidt, Christian, Blobner, Jens, von Bergwelt-Baildon, Michael, Tonn, Joerg-Christian, Kunz, Wolfgang G., Subklewe, Marion, von Baumgarten, Louisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Clinical/Scientific Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169944/ https://www.ncbi.nlm.nih.gov/pubmed/35351785 http://dx.doi.org/10.1212/WNL.0000000000200608

Ejemplares similares

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity
por: Stoecklein, Sophia, et al.
Publicado: (2023)

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report
por: Rejeski, Kai, et al.
Publicado: (2021)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
por: Schoeberl, Florian, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
por: Winkelmann, Michael, et al.
Publicado: (2022)

Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
por: Winkelmann, Michael, et al.
Publicado: (2023)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
por: Winkelmann, Michael, et al.
Publicado: (2023)

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
por: Cordas dos Santos, David M., et al.
Publicado: (2022)

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
por: Frölich, L., et al.
Publicado: (2022)

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
por: Rejeski, Kai, et al.
Publicado: (2023)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Shunt dependency in supratentorial intraventricular tumors depends on the extent of tumor resection
por: Teske, Nico, et al.
Publicado: (2023)

Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers
por: Karschnia, Philipp, et al.
Publicado: (2021)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE
por: Blumenberg, V., et al.
Publicado: (2022)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

Ten things the hematologist wants you to know about CAR-T cells
por: Böll, Boris, et al.
Publicado: (2020)

Advanced imaging findings in stroke-like migraine attacks after radiation therapy (SMART) syndrome
por: Teske, Nico, et al.
Publicado: (2022)

In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer
por: Xu, Tao, et al.
Publicado: (2023)

Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
por: Skalt, Daniela, et al.
Publicado: (2022)

Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice
por: Mulazzani, Matthias, et al.
Publicado: (2019)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

In vivo two-photon characterization of tumor-associated macrophages and microglia (TAM/M) and CX3CR1 during different steps of brain metastasis formation from lung cancer
por: Zhang, Wenlong, et al.
Publicado: (2021)

SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine
por: Karschnia, Philipp, et al.
Publicado: (2021)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
por: Unterrainer, Marcus, et al.
Publicado: (2020)

Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II
por: Karschnia, Philipp, et al.
Publicado: (2020)

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
por: Bücklein, Veit, et al.
Publicado: (2023)

Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma
por: Blobner, Jens, et al.
Publicado: (2023)

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
por: Banck, Jan Christoph, et al.
Publicado: (2021)

Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on (18)F-FDG PET/CT
por: Winkelmann, Michael, et al.
Publicado: (2020)

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022)

Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on (18)F-FDG PET/CT Imaging
por: Winkelmann, Michael, et al.
Publicado: (2021)

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
por: Philipp, Nora, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j4m9b4fjl9rufif4qn34du32m8